Neurodegeneration involves complex, cell-type-specific processes that are difficult to model accurately outside of human biology, contributing to poor translation in tau-mediated drug development. FloBiotech integrates human-relevant disease modeing with precision therapeutic programs to create a biologically grounded approach to studying and targeting neurodegenerative disease.
FloCells™ are designed to replicate tau-driven neurodegenerative disease biology in vitro, improving confidence in mechanistic relevance and candidate selection.
Built on human cellular systems that preserve key features of tau pathology observed in patient disease
Enables early differentiation between viable and non-viable therapeutic strategies prior to IND-enabling development
Supports modeling of tauopathies that are poorly served by existing systems, including PSP
Designed to inform go/no-go decisions and reduce late-stage attrition by aligning discovery with human biology
In parallel, our lead clusterin molecule targets a genetically validated vulnerability – reduced secreted clusterin (sCLU) associated with the CLU rs11136000 risk genotype – aiming to restore extracellular proteostasis and synaptic resilience.
Clusterin (CLU) is among the strongest genetic risk factors for sporadic Alzheimer’s disease, with large-scale genome-wide association studies (GWAS) consistently linking CLU varients to disease risk.
Approximately 80-90% of sporadic Alzhiemer’s disease patients carry the CLU rs11136000 C-risk genotype, which limits the ability to upregulate soluble Clusterin under pathological stress
In established Alzheimer’s disease models, Clusterin enhancement is associatd with statistically significant effects across molecular, functional and behavioral endpoints, supporting its role in modulating tau-related pathology and neuronal resilience
Grounded in human biology, our models deliver data that translates directly to patients.
FloCells™ are a proprietary human in-vitro platform designed to reproduce key aspects of tau-driven neurodegenerative disease biology in a controlled human cellular context.
By preserving disease-relevant tau pathology, FloCells™ enable earlier discrimination between viable and non-viable therapeutic strategies, supporting mechanistic insight and translational decision-making prior to IND-enabling development.
Key Advantages
Reduction in tau burden observed across FloCells™ Alzheimer’s models.
Improvement in translational accuracy versus animal and 2D models.
In partnership with UCLA Health® Flobiotech is developing FLO-1331, a first-in-class, oral, brain-penetrating small molecule designed to enhance soluble Clusterin in genetically defined patient populations.
Rather than blocking downstream pathology after damage has occurred, the Clusterin program is designed to support endogenous neuroprotective mechanisms and improve the brain’s ability to manage tau-related stress across multiple disease-relevant pathways.
Clinical Advantages
Designed for early intervention in tau-driven neurodegeneration
Potential to act across multiple disease-relevant pathways
Oral, brain-penetrant small molecule suitable for chronic administration
Precision-guided toward genetically defined patient populations
Accuracy in early biomarker pattern recognition across Alzheimer’s and FTD samples
Cellular profiles analyzed per study using AI clustering
By pairing human-relevant disease modeling with a genetically informed therapeutic strategy, FloBiotech’s approach is designed to reduce translational uncertainty at critical development decision points
This integrated strategy supports earlier risk reduction, clearer patient stratification, and more informed progression toward clincal development in tau-mediated neurodegenerative disease
FloBiotech’s pipeline translates human-relevant disease biology into development-read programs, with a focus on reducing translational uncertainty at critical decision points
Advancing precision therapeutic programs targeting tau-driven neurodegeneration, informed by human-relevant disease biology
Generating robust preclinical datasets to support IND-enabling decisions, guided by insights from human-relevant modeling
Collaborating with leading academic and clinical research groups to advance translational neuroscience and validate disease-relevant hypotheses
Extending FloCells™ to model additional tauopathies and disease-relevant stress pathways to support broader translational application
Advancing programs toward IND-enabling readiness through iterative integration of human-relevant modeling and preclinical evaluation
Establishing clear, data-driven development pathways from discovery through preclinical validation in tau-mediated neurodegenerative disease
Building bridges through collaborative science.